Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy

Irandi Jayatilleke; Alessandra Doolan; Jodie Ingles; Mark McGuire; Virginia Booth; David R Richmond; Christopher Semsarian

doi:10.1016/j.amjcard.2004.01.057

Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy

Am J Cardiol. 2004 May 1;93(9):1192-4. doi: 10.1016/j.amjcard.2004.01.057.

Authors

Irandi Jayatilleke¹, Alessandra Doolan, Jodie Ingles, Mark McGuire, Virginia Booth, David R Richmond, Christopher Semsarian

Affiliation

¹ Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Newtown, New South Wales, Australia.

PMID: 15110224
DOI: 10.1016/j.amjcard.2004.01.057

Abstract

In this study, high-risk patients with hypertrophic cardiomyopathy were treated with an implantable defibrillator. Long-term follow-up analysis showed the efficacy of implantable defibrillator therapy, with patients having an appropriate device intervention at a rate of 11%/year, thereby preventing sudden death in an Australian population.

Publication types

Evaluation Study
Research Support, Non-U.S. Gov't

MeSH terms

Adrenergic beta-Antagonists / therapeutic use
Adult
Australia
Cardiomyopathy, Hypertrophic / epidemiology
Cardiomyopathy, Hypertrophic / therapy*
Defibrillators, Implantable*
Follow-Up Studies
Humans
Hypertrophy, Left Ventricular / epidemiology
Hypertrophy, Left Ventricular / therapy
Middle Aged
Postoperative Complications / epidemiology
Postoperative Complications / etiology
Risk Factors
Sotalol / therapeutic use
Time
Treatment Outcome

Substances

Adrenergic beta-Antagonists
Sotalol